Celerion is the First CRO Headquartered in the USA to Receive Full Accreditation from AAHRPP
Celerion is the First CRO headquartered in the USA to Receive Full Accreditation from AAHRPP.
(Lincoln, NE; Sep 17, 2012) – Celerion, the premier provider of innovative early stage drug development solutions, is pleased to announce that it has been awarded full accreditation by the Association for the Accreditation Human Research Protection Programs (AAHRPP). Celerion’s clinical facilities in the USA; Lincoln NE; Neptune NJ; and Phoenix AZ, have achieved this significant milestone.
AAHRPP is an independent, non-profit accrediting body that uses a voluntary, peer-driven, educational model to ensure that Human Research Protection Programs (HRPPs) meet rigorous standards for quality and protection. To earn accreditation, organizations must provide tangible evidence—through policies, procedures, and practices—of their commitment to scientifically and ethically sound research and to continuous improvement.
To meet the full requirements for AAHRPP accreditation, Celerion reviewed all internal procedures and processes to ensure extensive safeguards were in place at every level of clinical research. Throughout the organization our teams evaluated their respective areas of responsibility, and reviewed policies, processes, and Standard Operating Procedures (SOPs). This ensured the highest levels of standards were adhered to, well documented and even more critical, translated into practice.
“The approval of AAHRPP certification continues to demonstrate the leadership role Celerion has taken to reach the highest standards and protections for human participants. By voluntarily undergoing the accreditation process, Celerion has committed to participants in our clinical studies that rigorous standards will be applied to ensure their safety and rights are strictly adhered to,” said Susan Thornton, Ph.D., President and CEO at Celerion. “This accreditation also highlights our commitment to increased quality and transparency in conducting ethically sound research for our clients.”
“I am pleased that Celerion is setting an example and raising the bar for research protections among CROs. With AAHRPP accreditation, Celerion now offers a level of quality assurance that distinguishes it among CROs and boosts its appeal to research clients,” said Marjorie A. Speers, Ph.D., AAHRPP President and CEO. “Our hope is that Celerion’s decision has a ripple effect across the research enterprise and that other CROs follow its lead.”
This accreditation places Celerion alongside a leading pharmaceutical company as well as Institutional Review Boards (IRBs), universities and hospitals to ensure we all collaborate in working with the highest standards in clinical research.
About Celerion
Celerion is the premier provider of innovative early stage clinical research solutions. Celerion has a full spectrum of resources to meet the needs of the pharmaceutical, biotechnology and generic industries for Phase 0 through IIa proof-of-concept studies. From facilities strategically located around the world, advanced scientific and technological expertise is applied to clinical research (Phases 0, I and IIa, NDA-enabling clinical pharmacology, ADME), clinical pharmacology sciences, bioanalytical services (discovery through late stage), and drug development services. For more information, visit www.celerion.com.
Media Contact:
Farzana Azam
Celerion
Executive Director, Global Marketing
media.inquiries@celerion.com